IMPORTANCE Glioma is the most commonly occurring malignant brain tumor in the United States, and its incidence varies by age, sex, and race or ethnicity. Survival after brain tumor diagnosis has been shown to vary by these factors.
G lioma is the most commonly occurring type of malignant brain tumor in the United States, with an average annual age-adjusted incidence rate (AAAIR) of 6.0 per 100 000 population from 2010 to 2014, 1 and causes significant morbidity and mortality. Glioblastoma, the most commonly occurring type of glioma, has a 5-year survival rate of approximately 5%. 1 Age and extent of resection (EOR) are 2 of the strongest prognostic factors in glioblastoma. 2 Incidence of glioma varies substantially by age, sex, and race or ethnicity; in the United States, incidence is highest among nonHispanic whites. 1 Glioma incidence also varies globally, with the highest rates in the United States, Canada, Australia, and Northern Europe. 3 Lifetime risk of developing a malignant brain tumor is more than twice as high among non-Hispanic whites (715/100,000) compared with blacks (347/100,000) and is 25% higher compared with Hispanic whites (559/100,000). 4 Survival rates after a diagnosis of malignant brain tumor also vary by race or ethnicity.
5,6
The few validated risk factors for glioma include history of allergies or atopic disease (which decreases risk) and exposure to ionizing radiation (which increases risk). 7 These risk factors explain a small proportion of glioma incidence and do not fully explain racial or ethnic differences in incidence. The purpose of this study was to use population-based data to quantify differences in glioma incidence and survival by race or ethnicity.
Methods
Data were obtained from the Central Brain Tumor Registry of the United States, through a data-release agreement with the Centers for Disease Control and Prevention National Program of Cancer Registries, which includes incidence data from approximately 99.9% of the US population. 1, 7 These data are derived from 51 central cancer registries (in 50 states and Washington, DC). The AAAIRs with 95% CIs were generated for adults (aged 18 years or older) using the SEER*Stat software, version 8.3.4 (Surveillance, Epidemiology, and End Results [SEER] Program). These data from January 1, 2000, to December 31, 2014, included glioma histologic groups, race or Hispanic ethnicity 8 (non-Hispanic white, Hispanic white, black, Asian or Pacific Islander, and American Indian or Alaska Native), sex, and age groups (18-34, 35-44, 45-54, 55-64, 65-74, and 75 years or older). Race information is abstracted by cancer registrars from medical records, which have been shown to have high sensitivity for blacks and moderate sensitivity for Hispanic whites. 9,10 Hispanic ethnicity is further classified using the North American Association of Central Cancer Registries Hispanic Identification algorithm, which uses a combination of data fields (medical record, birthplace, race, and surname) to directly and indirectly classify cases. 8 The data set used in this study was deidentified, and as a result the study protocol was ruled exempt from review by the University Hospitals Cleveland Medical Center Institutional Review Board. No patient informed consent was directly obtained. Data were collected from January 1, 2000, to December 31, 2014. Data analysis took place from December 11, 2017, to January 31, 2018.
All rates were standardized to the 2000 US population and reported per 100 000 population to adjust for differences in age distribution among racial or ethnic populations. Incidence rate ratios were generated from these standardized rates. Histologic groups were classified using the International Classification of Diseases for Oncology, Third Edition, codes and were defined according to the histologic grouping scheme of the Central Brain Tumor Registry of the United States (eTable 1 in the Supplement).
11 Most central cancer registries in the United States do not conduct active follow-up for outcomes. These data are publicly available from the National Cancer Institute SEER Program, which represents a subset (approximately 28%) of the cases included in the Central Brain Tumor Registry of the United States data set. 13, 14, 17 Survival data from 2000 to 2014
for adults at the time of diagnosis with histologic confirmation were included in survival analyses (followed until December 31, 2014, regardless of year of diagnosis). A custom data set was obtained containing additional treatment data fields, including chemotherapy and radiation treatments. 17 Although the treatment information in the SEER registries has been shown to have high positive predictive value (95% for radiation and 90% for chemotherapy), 18 its sensitivity is only moderate. The SEER Program strongly recommends that "no" values are treated as missing data and comparisons are not made between individuals identified as having treatment and those identified as having no treatment. As a result, treatment groups were defined using "yes" values for beam radiation and/or chemotherapy (see eTable 2 in the Supplement for information on treatment data completeness). One-year and 5-year relative survival (RS) rates were generated using SEER*Stat, version 8.3.4, by glioma histologic groups, race or ethnicity, and insurance status (available only for diagnosis years 2007 to 2014). Insurance status completeness is known to be poor for persons older than 65 years, who may be classified as being uninsured or having private insurance when they are Medicare-eligible. As a result, these data were used to evaluate survival in individuals aged 18 to 64 years only. Additional survival analyses were performed using Cox proportional hazard models adjusted for age and EOR in R, version 3.2.3 (R Foundation for Statistical Computing). We calculated 95% CIs using the method described in Tiwari et al 19 and P values for incidence rate ratios were calculated using the method documented in Fay et al. 20 All P values were 1-sided, and associations were considered significant at P < .05.
Results
Overall, from 2000 to 2014, there were 244 808 patients with glioma. Of these, 150 631 (61.5%) were glioblastomas, 46 002 (18.8%) were non-glioblastoma astrocytomas, 26 068 (10.7%) were oligodendroglial tumors, 8816 (3.6%) were ependymomas, and 13 291 (5.4%) were other glioma diagnoses in adults (eTable 3 in the Supplement). The data set included 137 733 males (56.3%) and 107 075 (43.7%) females. There were 204 580 non-Hispanic whites (83.6%), 17 321 Hispanic whites (7.08%), 14 566 blacks (6.0%), 1070 American Indians or Alaska Natives (0.4%), and 5947 Asians or Pacific Islanders (2.4%). Glioblastoma incidence was highest in non-Hispanic whites (AAAIR, 4.71; 95% CI, 4.69-4.74) and lowest in American Indians or Alaska Natives (AAAIR, 1.88; 95% CI, 1.71-2.06), where incidence was approximately 40% that of non-Hispanic whites (Figure 1;eTable3intheSupplement) . Incidence was highest in males (incidence rate ratio [IRR], 1.59; P < .005). The male to female IRR was highest in Asians or Pacific Islanders (IRR, 1.65) and lowest in Hispanic whites (IRR, 1.49). The median age varied by race or ethnicity, with non-Hispanic whites having the highest median age (64 years) and blacks and American Indians or Alaska Natives having the lowest (59 years). Incidence rates were highest in the age 65 years or older group (eFigure and eTable 4 in the Supplement).
Overall, the 1-year RS after diagnosis was 41.4% (95% CI, 40.8-42.0) and the 5-year RS was 5.4% (95% CI, 5.1-5.7) (Table) . The highest 5-year RS was observed in Asians or Pacific Islanders (8.8%; 95% CI, 7.0-10.9) and the lowest in non-Hispanic whites (4.8%; 95% CI, 4.5-5.2). To evaluate the potential period effects between the pre-and post-Stupp treatment (concurrent radiation and temozolomide 21 ) protocol eras (2000-2004 and 2005-2014) , RS was evaluated separately within each period. The RS was generally higher in the post-Stupp era (Table) . There was no change in the 5-year RS for Asians or Pacific Islanders between the 2 periods, whereas the 1-year RS increased from 39.3% (95% CI, 33.9-44.6) to 54.2% (95% CI, 50.8-57.4). Among those who received radiation, the 1-year RS was highest in Asians or Pacific Islanders (63.1%), whereas the 5-year RS was highest in Hispanic whites (9.6%). For those who 
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Adult Glioma Incidence and Survival by Race or Ethnicity received both radiation and chemotherapy, the 1-year and 5-year RS rates were highest in Asians or Pacific Islanders (67.1% and 10.1%) and lowest in non-Hispanic whites (57.2% and 6.6%). For persons aged 18 to 34 years, non-Hispanic whites had the highest 1-year and 5-year survival (78.6% and 27.0%) (eTable 5 in the Supplement). In the 35 to 44 years age cohort, survival was highest among Hispanic whites, with a 1-year RS of 69.6% and a 5-year RS of 19.3%. For all cohorts aged 45 years or older, Asians or Pacific Islanders had the highest survival rate. When survival models were adjusted for EOR and age, being Asian or Pacific Islander was a significant predictor of increased survival (P = 2.4x10 −5 ; Figure 2 ;e T a b l e6i nt h e Supplement). Among only those who received surgery, radiation, and chemotherapy, all racial or ethnic groups had significantly improved survival compared with non-Hispanic whites (see eTable 2 in the Supplement for the completeness of treatment information). Non-glioblastoma astrocytoma incidence was highest in non-Hispanic whites (AAAIR, 1.55; 95% CI, 1.54-1.57) and lowest in blacks (AAAIR, 0.74; 95% CI, 0.72-0.77), where incidence was approximately 48% that of non-Hispanic whites ( Figure 1 ; eTable 3 in the Supplement). Overall incidence was highest in males (IRR, 1.35; P < .005). The male to female IRR was highest in non-Hispanic whites (IRR, 1.55) and Asians or Pacific Islanders (IRR, 1.55) but lowest in American Indians or Alaska Natives, where no significant sex difference was observed (IRR, 1.08; P = .58). The median age varied by race or ethnicity, with non-Hispanic whites having the highest (50 years) and Hispanic whites, Asians or Pacific Islanders, and American Indians or Alaska Natives having the lowest (41 years). Incidence rates were highest in the 65-74 years age cohort in all race or ethnicity groups except Asians or Pacific Islanders, where the highest incidence was in persons 75 years or older (eFigure and eTable 4 in the Supplement).
Overall, the 1-year RS after diagnosis of non-glioblastoma astrocytomas was 72.4% (95% CI, 71.5-73.3) and the 5-year RS was 44.4% (95% CI, 43.3-45.5) (Table) . The highest 5-year RS was observed in Hispanic whites (50.8%; 95% CI, 47.5-53.9) and the lowest in non-Hispanic whites (43.2%; 95% CI, 41.9-44.4). For persons aged 18 to 44 years, non-Hispanic whites had the highest 1-year and 5-year RS, whereas in older age groups the highest 5-year RS was in Hispanic whites (eTable 5 in the Supplement). When survival models were adjusted for EOR and age, there was no significant association between survival and any race or ethnicity group (Figure 2 ; eTable 6 in the Supplement).
Oligodendroglial tumors incidence was highest in nonHispanic whites (AAAIR, 0.92; 95% CI, 0.91-0.93) and lowest in blacks (AAAIR, 0.33; 95% CI, 0.31-0.35), where incidence was approximately 36% that of non-Hispanic whites (Figure 1 ; eTable 3 in the Supplement). Overall incidence was highest in males (IRR, 1.33; P < .005). The male to female IRR was highest in non-Hispanic whites (IRR, 1.33) and lowest in Hispanic whites, where there was no significant sex difference (IRR, 1.17). The median age varied by race or ethnicity, with the highest in non-Hispanic whites (44 years) and the lowest in American Indians or Alaska Natives (36 years). Incidence rates were highest in the 35 to 44 years age cohort in non-Hispanic whites, blacks, and Asians or Pacific Islanders; incidence rate in American Indians or Alaska Natives was highest in the 18 to 34 years cohort; and incidence rate in Hispanic whites was highest in the 45 to 54 years age group (eFigure and eTable 4 in the Supplement).
Overall, the 1-year RS after diagnosis of oligodendroglial tumors was 90.4% (95% CI, 89.6-91.1) and the 5-year RS was 70.0% (95% CI, 68.5-71.4) (Table) . The highest 5-year RS was observed in Hispanic whites (73.9%; 95% CI, 70.3-77.1) and lowest in blacks (63.8%; 95% CI, 57.1-69.7). The 1-year and 5-year RS increased from 2005 to 2014, but these increases were minimal. For individuals aged 18 to 44 years, non-Hispanic whites had the highest 1-year and 5-year RS, whereas in older age groups, the highest 5-year RS was in Hispanic whites (eTable 5intheSupplement). When survival models were adjusted for EOR and age, no significant association was found between survival rate and any race or ethnicity group (Figure 2 ; eTable 6 in the Supplement).
Ependymoma incidence was highest in non-Hispanic whites (AAAIR, 0.29; 95% CI, 0.28-0.29) and lowest in American Indians or Alaska Natives (AAAIR, 0.13; 95% CI, 0.09-0.17), where incidence was approximately 45% that of non-Hispanic whites (Figure 1 ; eTable 3 in the Supplement). Incidence of ependymoma was slightly higher in males (IRR, 1.33; P < .005). The male to female IRR was highest in nonHispanic whites (IRR, 1.11), and there was no significant sex difference in incidence in any other group. The median age varied by race or ethnicity, with non-Hispanic whites having the highest (59 years) and Hispanic whites having the lowest (47 years). Incidence of ependymoma was highest in the 45 to 74 years age group in all race or ethnicity groups (eFigure and eTable 4 in the Supplement). Overall, the 1-year RS after diagnosis of ependymoma was 94.3% (95% CI, 93.1-95.3) and the 5-year RS was 88.0% (95% CI, 86.2-89.6) (Table) 
Discussion
The present study of glioma incidence and survival across a 14-year period demonstrates substantial variation by race or ethnicity, using data from 99.9% of the US population to derive incidence rates and data from approximately 28% of the population to obtain survival rates.
22,23 Non-Hispanic whites had the highest incidence of all glioma subtypes, consistent with what has been previously reported. 1, 18, 21 The median age of diagnosis for all histologies was highest also among nonHispanic whites. There was a male preponderance in incidence of most glioma histologies among all examined racial or ethnic groups, and the scale of the male to female IRR was similar among all race or ethnicity groups. Analyses have consistently found higher glioma incidence in non-Hispanic whites as well as in countries with high proportions of individuals with mostly European ancestry. 1, 3 The reason for this finding may be, to some extent, the variation in genetic risk susceptibility for glioma, but to date no studies have examined the inherited risk variants associated with glioma risk in blacks or Hispanic whites.
A portion of this incidence difference may be the result of several biases. Incidence estimates are sensitive to ascertainment bias, because of differential access to health care or the variation in diagnostic procedure. Non-Hispanic whites often have improved access to health care, which may lead to earlier or more accurate diagnosis. 22, 23 Glioma is usually symptomatic (incidental diagnoses represent approximately 2% to 6% of diagnoses in case series studies [24] [25] [26] ) and often presents with substantial symptoms, including seizures and cognitive impairments. As a result, the chance of ascertainment bias resulting in considerable underdiagnosis is small. Heterogeneous reporting guidelines or the application of histologic classification schemes could result in spuriously different rates among racial or ethnic groups. There is no central pathology review of tumor samples in the data used for this analysis, but it is possible that "true" histologic classification could be confounded with race or ethnicity. Although these factors may affect incidence rates, they fail to explain the incidence difference between non-Hispanic whites and other groups. Previous analyses have found substantial associations between increased socioeconomic status and glioma, which may contribute to differences in incidence by race or ethnicity.
27-29
A previous SEER analysis found increased incidence of glioma in areas of higher socioeconomic status after adjusting for sex, race, and age. 28 In Sweden, the highest glioma incidence was among those with family incomes in the highest quartile (odds ratio [OR], 1.5; 95% CI, 1.1-2.1), after adjusting for sex, age, and geographic region. 29 The underlying risk factors responsible for differential incidence by socioeconomic status are unknown but could be partially the result of confounding with known or currently unknown risk factors. high school diploma compared with the general US population, which may also affect survival estimates.
35
This analysis found that non-Hispanic whites had poorer outcomes after diagnosis of glioblastoma when compared with all other groups. This pattern was present in both the pre-and post-Stupp protocol era period analyses (Table) among those who received treatment beyond resection (eTable 7 in the Supplement) as well as after adjustment for age and EOR (Figure 2) . A large US meta-analysis previously reported that blacks have lower 5-year survival rate compared with whites after diagnosis of central nervous system cancers.
36 These disparities were reduced after adjustment for disease severity, treatment type, and the underlying mortality rate. Curry et al 5 remark that blacks presented with greater disease severity and that there is lower annual cancer-associated craniotomy case volume in the National Inpatient Sample data for patients with Medicaid insurance. Variations in health care access and severity at the time of presentation are likely substantial contributors to the variation in survival patterns.
Furthermore, this analysis found that non-Hispanic whites have a lower survival rate compared with other racial or ethnic groups. People who are not non-Hispanic whites have comparatively low numbers of cases, and some of the observed differences may be the result of these low numbers. These findings are in line with those of some previously reported analyses, such as a SEER study that found increased survival in blacks compared with whites after diagnosis of a central nervous system tumor. 37 These differences were consistently observed within sex and across age strata. Both 1-year and 5-year survival rates were lower among non-Hispanic whites, particularly compared with Hispanic whites, regardless of treatment type. This previous analysis also found that differences persisted in glioblastoma among those who received radiation and chemotherapy, suggesting that health care access is not sufficient to explain survival differences.
In older cohorts who have universal access to Medicare, access to health care and treatment type may not adequately explain differential survival rates. For all ages, other factors should be explored in future studies. Survival after diagnosis of cancer of other sites has been shown to correlate with many factors that also vary by race or ethnicity, including body mass index, smoking status, and religious service attendance.
38-40
Although prediagnostic body mass index has been associated with shorter survival after diagnosis of glioma, these additional factors have not all been sufficiently explored. 41 46 As a result, these molecular classifications were not incorporated into this analysis, and it is not possible to assess whether these may be driving the observed survival differences. An analysis of time trends by race or ethnicity and glioma histologic subtype (eTable 9 in the Supplement) shows substantial decreases in incidence of oligodendroglial tumors in all groups over the period examined in this study, which may be the result of changing classification schemes.
Conclusions
To our knowledge, this study represents the most complete and up-to-date reporting of patterns of glioma incidence and survival by race or ethnicity in the United States. These estimates of incidence are population-based and include approximately 99.9% of the US population, while SEER data cover approximately 28% of the population. 22 Incidence and survival patterns of most glioma histologies varied significantly by race or ethnicity, with non-Hispanic whites having higher incidence and lower survival compared with individuals of other race or ethnicity. Further examination is necessary to determine the factors that contribute to these differences. Expanding investigations of germline genetic associations in blacks and Hispanic whites may identify genetic contributions to incidence differences. Somatic characterization of tumors in multiethnic cohorts is also necessary to determine that the observed survival differences may not be due to differences in proportions of molecular subtypes within histologic subtypes among racial or ethnic groups. Examination of treatment patterns in databases with more extensive clinical information is necessary to determine the extent to which health care access may affect differences in outcomes. 
